Genelux (NASDAQ:GNLX – Get Free Report) and Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
Insider & Institutional Ownership
37.3% of Genelux shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Genelux and Lisata Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genelux | $10,000.00 | 13,138.12 | -$32.15 million | ($0.85) | -3.45 |
| Lisata Therapeutics | $170,000.00 | 179.52 | -$16.59 million | ($1.86) | -1.80 |
Lisata Therapeutics has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Genelux and Lisata Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genelux | N/A | -174.55% | -123.65% |
| Lisata Therapeutics | N/A | -103.54% | -83.08% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Genelux and Lisata Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genelux | 1 | 0 | 3 | 0 | 2.50 |
| Lisata Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Genelux currently has a consensus target price of $18.00, indicating a potential upside of 514.33%. Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 347.76%. Given Genelux’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Genelux is more favorable than Lisata Therapeutics.
Volatility and Risk
Genelux has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Summary
Lisata Therapeutics beats Genelux on 7 of the 13 factors compared between the two stocks.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
